Multi-marker testing for cancer: What can we learn from modern prenatal testing for Trisomy-21

Cancer Informatics

Volumn 2, Issue , 2006, Pages 44-47

  Schneider, Erasmus ^a   Mizejewski, Gerald ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 724 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; COLONY STIMULATING FACTOR 1; LIPID ASSOCIATED SIALIC ACID; OVX1 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ALGORITHM; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER TEST; CHEMICAL ANALYSIS; CHROMOSOME ABERRATION; DIGITAL RECTAL EXAMINATION; DOWN SYNDROME; HUMAN; KARYOTYPE; LOGISTIC REGRESSION ANALYSIS; MATERNAL SERUM; PRENATAL CARE; PRENATAL DIAGNOSIS; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TRISOMY 21;

EID: 33744948563     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.1177/117693510600200028     Document Type: Review

References (38)

1. Aitken DA, Wallace EM, Crossley JA, et al. (1996). "Dimeric inhibin A as a marker for Down's syndrome in early pregnancy." N Engl J Med 334 (19): 1231-6.
2. Babaian RJ, Fritsche HA, Zhang Z, et al. (1998). "Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report." Urology 51(1): 132-6.
3. Bast RC, Jr., Badgwell D, Lu Z, et al. (2005). "New tumor markers: CA125 and beyond." Int J Gynecol Cancer 15 Suppl 3: 274-81.
4. Bast RC, Jr., Xu FJ, Yu YH, et al. (1998). "CA 125: the past and the future." Int J Biol Markers 13(4): 179-87.
5. Bauer JJ and Moul JW (2000). Assessment of risk of prostate cancer: algorithms for diagnosis, staging, and prognosis. Advanced therapy of prostate disease. M. I. Resnick and I. M. Thompson. Lewiston, NY, B.C. Decker: 34-43.
6. Berek JS and Bast RC, Jr. (1995). "Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection." Cancer 76(10 Suppl): 2092-6.
7. Bogart MH, Pandian MR and Jones OW (1987). "Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities." Prenat Diagn 7(9): 623-30.
8. Catalona WJ, Richie JP, Ahmann FR, et al. (1994). "Comparision of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men." J. Urol. 151: 1283-1290.
9. Catalona WJ, Smith DS, Wolfert RL, et al. (1995). "Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening." JAMA 274: 1214-1220.
10. Cuckle HS, Wald NJ, Barkai G, et al. (1988). "First-trimester biochemical screening for Down syndrome." Lancet 2(8615): 851-2.
11. Cuckle HS, Wald NJ and Thompson SG (1987). "Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level." Br J Obstet Gynaecol 94(5): 387-402.
12. Dugoff L, Hobbins JC, Malone FD, et al. (2004). "First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial)." Am J Obstet Gynecol 191(4): 1446-51.
13. Gordon S. (2005). "Test Detects Down Syndrome Early." Forbes Retrieved Dec. 15, 2005, from http://www.forbes.com/lifestyle/health/feeds/ hscout/2005/11/09/hscout529032.html.
14. Hook EB (1976a). "Estimates of maternal age-specific risks of Downsyndrome birth in women aged 34-41." Lancet 2(7975): 33-4.
15. Hook EB (1976b). "Risk of Down syndrome in relation to maternal age." Lancet 2(7983): 465.
16. Kamoi K and Babaian RJ (1999). "Advances in the application of prostatespecific antigen in the detection of early-stage prostate cancer." Semin Oncol 26(2): 140-9.
17. Li J, Orlandi R, White CN, et al. (2005). "Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry." Clin Chem 51(12): 2229-35.
18. Malone FD, Canick JA, Ball RH, et al. (2005). "First-trimester or secondtrimester screening, or both, for Down's syndrome." N Engl J Med 353(19): 2001-11.
19. Petricoin EF, Ardekani AM, Hitt BA, et al. (2002). "Use of proteomic patterns in serum to identify ovarian cancer." Lancet 359(9306): 572-7.
20. Postma R and Schröder FH (2005). "Screening for prostate cancer." Eur J Cancer 41(6): 825-33.
21. Raaijmakers R, Blijenberg BG, Finlay JA, et al. (2004). "Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness." J Urol 171(6 Pt 1): 2245-9.
22. Schröder FH, Roobol-Bouts M, Vis AN, et al. (2001). "Prostate-specific antigen-based early detection of prostate cancer - validation of screening without rectal examination." Urology 57(1): 83-90.
23. Schröder FH, van der Maas P, Beemsterboer P, et al. (1998). "Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer." J Natl Cancer Inst 90(23): 1817-23.
24. Skates SJ, Horick N, Yu Y, et al. (2004). "Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions." J Clin Oncol 22 (20): 4059-66.
25. Stephan C, Cammann H, Semjonow A, et al. (2002a). "Multicenter Evaluation of an Artificial Neural Network to Increase the Prostate Cancer Detection Rate and Reduce Unnecessary Biopsies." Clin Chem 48(8): 1279-1287.
26. Stephan C, Jung K, Cammann H, et al. (2002b). "An artificial neural network considerably improves the diagnostic power of percent free prostatespecific antigen in prostate cancer diagnosis: results of a 5-year investigation." Int J Cancer 99(3): 466-73.
27. Terry KL, Sluss PM, Skates SJ, et al. (2004). "Blood and urine markers for ovarian cancer: a comprehensive review." Dis Markers 20(2): 53-70.
28. Vis AN, Hoedemaeker RF, Roobol M, et al. (2001). "Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)." Prostate 47(4): 252-61.
29. Wald NJ, Cuckle HS, Sneddon J, et al. (1989). "Screening for Down syndrome." Am J Hum Genet 44(4): 586-90.
30. Wald NJ, Densem JW, Smith D, et al. (1994a). "Four-marker serum screening for Down's syndrome." Prenat Diagn 14(8): 707-16.
31. Wald NJ and Hackshaw AK (1997). "Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome." Prenat Diagn 17(9): 821-9.
32. Wald NJ, Kennard A and Hackshaw AK (1995). "First trimester serum screening for Down's syndrome." Prenat Diagn 15(13): 1227-40.
33. Wald NJ, Kennard A and Smith D (1994b). "First trimester biochemical screening for Down's syndrome." Ann Med 26(1): 23-9.
34. Wald NJ, Rodeck C, Hackshaw AK, et al. (2003). "First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS)." Health Technol Assess 7(11): 1-77.
35. Wallis C. (2005). "The Down Dilemma." Time Retrieved Dec. 15, 2005, from http://www.time.com/time/archive/preview/0,10987,1129545,00.html.
36. Woolas RP, Conaway MR, Xu F, et al. (1995). "Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses." Gynecol Oncol 59(1): 111-6.
37. Zhang Z, Bast RC, Jr., Yu Y, et al. (2004). "Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer." Cancer Res 64(16): 5882-90.
38. Zhang Z, Zhang H and Bast RC (2000). An application of artificial neural networks in ovarian cancer early detection. IEEE-INNS-ENNS Internationa Joint Conference on Neural Networks (IJCNN'00).